

Xu Cheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3150873/publications.pdf>

Version: 2024-02-01

27
papers

3,873
citations

394421

19
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

8581
citing authors

#	ARTICLE	IF	CITATIONS
1	A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis. <i>Hepatology</i> , 2022, 75, 403-418.	7.3	15
2	Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1. <i>Hepatology</i> , 2022, 75, 1507-1522.	7.3	10
3	Tripartite motif-containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome-mediated degradation of pleckstrin homology domain leucine-rich repeats protein phosphatase 1. <i>Hepatology</i> , 2022, 76, 612-629.	7.3	10
4	Kidney Function Indicators Predict Adverse Outcomes of COVID-19. <i>Med</i> , 2021, 2, 38-48.e2.	4.4	47
5	A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. <i>Cell Metabolism</i> , 2021, 33, 1171-1186.e9.	16.2	10
6	CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 268.	17.1	27
7	TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. <i>Cell Metabolism</i> , 2021, 33, 1640-1654.e8.	16.2	22
8	Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD. <i>Hepatology</i> , 2021, 74, 1319-1338.	7.3	11
9	TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury. <i>Hepatology</i> , 2021, 74, 2133-2153.	7.3	20
10	Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. <i>Cell Metabolism</i> , 2021, 33, 2059-2075.e10.	16.2	35
11	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	12.4	30
12	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabg8117.	12.4	23
13	Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3. <i>Hepatology</i> , 2020, 71, 1592-1608.	7.3	23
14	Three-dimensional cell models for extracellular vesicles production, isolation, and characterization. <i>Methods in Enzymology</i> , 2020, 645, 209-230.	1.0	1
15	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 32, 537-547.e3.	16.2	116
16	Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. <i>Hypertension</i> , 2020, 76, 1104-1112.	2.7	118
17	Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 892-908.e11.	16.2	92
18	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <i>Cell Metabolism</i> , 2020, 32, 176-187.e4.	16.2	400

#	ARTICLE	IF	CITATIONS
19	Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. <i>Hepatology</i> , 2020, 72, 389-398.	7.3	346
20	Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 31, 1068-1077.e3.	16.2	1,207
21	TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. <i>Cell Metabolism</i> , 2020, 31, 726-740.e8.	16.2	60
22	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. <i>Circulation Research</i> , 2020, 126, 1671-1681.	4.5	948
23	No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. <i>World Journal of Clinical Cases</i> , 2020, 8, 5576-5588.	0.8	26
24	Integrated Omics Reveals Tollip as an Regulator and Therapeutic Target for Hepatic Ischemia-Reperfusion Injury in Mice. <i>Hepatology</i> , 2019, 70, 1750-1769.	7.3	44
25	Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor β in Mice. <i>Hepatology</i> , 2019, 69, 2471-2488.	7.3	37
26	An ALOX12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. <i>Nature Medicine</i> , 2018, 24, 73-83.	30.7	155
27	Hybrid sequencing and map finding (HySeMaFi): optional strategies for extensively deciphering gene splicing and expression in organisms without reference genome. <i>Scientific Reports</i> , 2017, 7, 43793.	3.3	24